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Altered patterns of the interferon-inducible gene IFI16 expression in head and neck squamous
cell carcinoma: immunohistochemical study including correlation with retinoblastoma
protein, human papillomavirus infection and proliferation index
Aims: To investigate whether the expression of inter-
feron (IFN)-inducible gene IFI16 is inversely related to
proliferative activity in vivo, we compared immunoh-
istochemical reactivity of IFI16 in a series of head and
neck squamous cell carcinomas (HNSCCs) with their
proliferation index and the cell cycle regulator pRb. As
human papillomavirus (HPV) infection is manifested by
changes in the function or expression level of host
genes such as IFN-inducible genes, we also investigated
the presence of HPV DNA to determine whether head
and neck cancers associated with HPV DNA can be
distinguished from tumours that are presumably
transformed by other mechanisms.
Methods: Thirty-six HNSCCs were evaluated for IFI16,
pRb and Ki67 expression by immunohistochemistry.
The presence of HPV was also detected by polymerase
chain reaction. Nine tumours were located in the
oropharynx (tonsillar area) and 27 in the larynx.
Results: HPV DNA was found in 14 of 25 (56%)
laryngeal SCCs and in five of nine (56%) tonsillar SCC
specimens examined; 17 out of the 19 HPV-DNA-
positive cases showed high-grade IFI16 expression.
Overall, proliferative activity was significantly related
to tumour differentiation and histological grading.
IFI16 protein expression was significantly inversely
correlated with Ki67 (P ¼ 0.039). Low-proliferating
tumours positive for IFI16 staining showed a marked
expression of pRb and a better prognosis than those
whose tumours had low IFI16, pRb levels and a high
proliferation index.
Conclusions: To our knowledge, this is the first expres-
sion analysis of the IFN-inducible IFI16 gene in
HNSCC. Low-proliferating tumours positive for IFI16
staining showed a marked expression of pRb and a
better prognosis than those whose tumours had low
IFI16, pRb levels and a high proliferation index.
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Introduction
Human malignancies arising in the head and neck
region are a significant cause of morbidity and mortal-
ity worldwide.1 Their epidemiology has been well
described, whereas the molecular steps involved in
their pathogenesis are poorly understood. Mucosotro-
pic high-risk papillomaviruses (HPVs) known to cause
cervical and anogenital cancers have been proposed to
play a role in the aetiology of some head and neck
squamous cell carcinomas (HNSCCs).2–5 The presence
of high-risk HPV DNA in a subgroup of HNSCCs
supports this hypothesis.6
Molecular studies have provided important data on
the role and oncogenic mechanisms of high-risk HPV in
carcinogenesis. By expression of the viral oncoproteins
E6 and E7, the virus dysregulates crucial cellular
mechanisms, such as the cell cycle and the apoptotic
pathway, by inhibiting the activity of the cellular p53
and Rb tumour suppressor proteins, respectively.7,8
Moreover, some in vitro studies have demonstrated the
ability of HPV oncoproteins to control signalling
pathways that lead to the expression of interferon
(IFN) and IFN-inducible genes.9,10 It has been reported
that HPV16 E6 binds to the carboxyl-terminal domain
of transcription factor IRF3 and inactivates its trans-
activating function.11 Expression of HPV16 E6
in human keratinocytes diminishes the induction of
IFN-b gene expression by Sendai virus and conse-
quently the expression of IFN-inducible genes. By using
microarray analysis Chang and Laimins have identified
IFN-inducible genes and STAT-1 as major targets of
HPV31.12,13 Lastly, Nees et al. have used the same
technique to demonstrate that HPV16 E6 in cervical
keratinocytes decreases the expression of IFN-a and -b,
down-regulates nuclear STAT-1 protein, and decreases
its binding to the IFN-stimulated response element.14
The IFN-inducible genes comprise members of the
HIN-200 (haematopoietic interferon-inducible nuclear
proteins with a 200-amino-acid repeat) gene family
found on human and mouse chromosome 1.15,16 This
family consists of a number of highly homologous
human and murine proteins with similar primary
amino acid sequences and biological characteristics.
The mouse HIN-200 family includes Ifi202, Ifi204,
Ifi203 and D3, while the human family includes IFI16,
MNDA (myeloid nuclear differentiation antigen) and
AIM2 (absent in melanoma 2). A highly conserved
200-amino-acid domain present singly or in duplicate
is a structural motif found in all members which
harbours an LXCXE motif that is a potential site for
binding to the retinoblastoma gene product.17 Over-
expression of the 204 protein, encoded by the mouse
Ifi204 member, in mouse embryo fibroblasts (MEF)
retarded their proliferation, delayed G1 progression into
S-phase and led to an accumulation of cells with a DNA
content equivalent to cells arrested in late G1.
18,19
These effects on cell cycle progression were strictly
dependent on the association of p204 with the Rb
protein.20,21 Moreover, over-expression of the p204dm
inactivated by mutation at both LXCXE motifs increases
cell proliferation and leads to malignant transformation
capability, such as growth under low-serum conditions
and formation of tumours in athymic nude mice.22
Altogether these results suggest a strict correlation
between Ifi204 expression and inhibition of cell
growth.
All HIN-200 family members are expressed in
haematopoietic cells, and some molecules show a
tightly regulated expression pattern in certain cell
types.23,24 Recent findings from our and other labor-
atories in normal adult human tissues have shown that
IFI16 is also expressed in epithelial and endothelial
cells.25,26 Prominent IFI16 expression is seen in stra-
tified squamous epithelia, particularly intense in basal
cells in the proliferating compartments, whereas it
gradually decreases in the suprabasal more differenti-
ated compartment. In the cervix, only the squamous
epithelium of the exocervix was positive, whereas the
glandular mucosa of the endocervix was negative.
Expression of IFI16 in the most basal, rapidly cycling
cells appears counter to the proposed function of HIN-
200 proteins in negatively regulating cell growth. This
expression pattern in squamous epithelia is therefore
somewhat similar to that seen in the haematopoietic
system, with IFI16 being highly expressed in progen-
itor stem cells and some differentiated cell types
(i.e. lymphocytes, monocytes), yet not expressed in
granulocytes and macrophages.23 These results there-
fore indicate that mere expression of IFI16 may not be
sufficient to inhibit cell growth. Its selective expression
in some cell lineages, high level in basal squamous
epithelial cells, and loss of expression in many cells
following or during differentiation indicate that it may
be involved in regulating cell differentiation or prolif-
eration. Consistent with a role for p200-family proteins
in cell growth regulation, there are indications that
viral oncoproteins functionally inactivate p202.27
Expression of AIM2 is lost by frame-shift mutations in
colorectal tumours, and loss of MNDA expression in
prostate carcinoma is linked to progression to more
aggressive metastatic prostate cancer.28,29 Recent
studies have revealed that increased levels of IFI16 in
prostate epithelial cells contribute to senescence-
associated irreversible cell growth arrest. Moreover,
its over-expression in human prostate cancer cell lines,
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that did not express IFI16, inhibited colony forma-
tion.30 Altogether, these observations support the idea
that the loss of function of p200-family proteins, by
providing growth advantage to the affected cells, may
contribute to the development of cancer.
To define whether IFI16 expression reflects a genetic
change in multistep cancer transformation, we ana-
lysed the relationship between its expression, tumour
proliferation, grade of differentiation, and expression of
a well-known tumour suppressor (pRb) in HNSCC.
In the present study, we demonstrate the correlation
between IFI16 expression, HPV status, and low prolif-
eration index in a series of HNSCCs and discuss its
biological relevance.
Materials and methods
patients and tumour specimens
Patients with a diagnosis of SCC of the head and
neck region and treated at the Maggiore Hospital,
Novara, were identified through the surgical pathol-
ogy files and tumour registry. Clinical information
was collected by chart review. The clinical staging
and identification of the anatomical site of the
tumours were based on the International Union
Against Cancer (1987) TNM classification of malig-
nant tumours.31 Thirty-six patients who underwent
surgical treatment for SCC of the upper aerodigestive
tract were included. The distribution of the tumours
by anatomical site was as follows: 27 tumours in the
larynx, of which 12 were assigned as supraglottic
and 15 as glottic, and nine in the tonsil. The age of
the patients ranged from 45 to 87 years (mean
63 years). Thirty-one patients were male and five
were female. The follow-up of the patients ranged
from 9 to 98 months (mean 37.5). The diagnosis and
assessment of the grade of differentiation were made
according to Wiernik et al.32 on haematoxylin and
eosin-stained sections from 10% buffered formalin-
fixed paraffin-embedded tissues.
immunohistochemistry
Immunohistochemical analysis was performed on sec-
tions from the same paraffin-embedded tissue placed on
silane-coated glass slides. In brief, sections were depa-
raffinized, and the endogenous peroxidase activity was
blocked with 0.3% H2O2 in 1 · PBS. For antigen
retrieval, the slides were placed in a Coplin jar filled with
a10 mm trisodiumcitrate solution at pH 6.0, andheated
for 26 min at 750 Wand then for 15 min at 300 W in a
conventional pressure cooker underwent cycle in a
microwave oven. Slides were incubated in blocking
solution (5% donor serum plus 0.2% Triton X100 in
PBS) to prevent non-specific binding and then with an
optimal dilution of the primary antibody (1 : 5000 for
the rabbit polyclonal anti-carboxy-terminal IFI16).25
After washing in 1 · PBS, they were incubated with the
appropriate biotinylated secondary antibody, followed
by streptavidin–horseradish peroxidase complex (Im-
munotech, Marseille, France). Immunostaining was
performed by incubation of the slides in diaminobenzi-
dine solution (DAB) (Roche, Mannheim, Germany); the
enzymatic reactionwasmonitored under a conventional
microscope. Finally, slides were counterstained with
haematoxylin for 30 s, dehydrated, and mounted with
Eukitt (Bioptica, Milan, Italy). In all experiments, a
routine control was included in which the primary
antibody was omitted. The substitution of the antibody
with preimmune serum was the internal control. IFI16
immunostaining was confined to the nuclei in both
neoplastic and non-neoplastic cells. In all peritumoral
normal epithelia, only the nuclei of the basal and para-
basal cells were positive. In positive tumours, more than
50% of neoplastic cells expressed IFI16. As expected,
IFI16 was detected in the nuclei of reactive fibroblasts,
endothelial cells, and some inflammatory cells surround-
ing the cancer tissue. These non-neoplastic cells were
always stained, and this served as an internal positive
control when lesions were judged negative.
The immunoreactivity for pRb was assessed using
the Rb (C-15) rabbit polyclonal antibody (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA, USA). Slides were
incubated with the antibody at 1 : 1000 dilution for
1 h at room temperature and processed as described
above. Immunohistochemical staining for the prolifer-
ative fraction was performed with the Ki67 ⁄MIB-1
mouse monoclonal antibody (Immunotech) at
1 : 1000 dilution as described. The percentage of
positive cells was assessed in each case and the staining
was divided into two categories: < or >20% of Ki67+
cells, as reported in Table 1.
All slides were reviewed and scored in a blind test by
two pathologists (M.P. and G.V.).
dna extraction
A modified version of the Wright and Manos method
(PCR protocols: a guide to methods and applications. New
York: Academic Press, 1990) was used for DNA
extraction.33 One to three 10-lm sections were taken
from the paraffin block, placed in a 1.5-ml plastic tube
containing 150 ll of digestion buffer (50 mm Tris–HCl,
1 mm EDTA, 0.5% Tween 20) and 0.2 mg ⁄ml pro-
teinase K (Roche). Samples were incubated for 4 h at
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65C. Protease was then destroyed by a 5-min incu-
bation at 95C and the samples were immediately
centrifuged for 5 min at 11 000 g.
The concentration of the extracted DNA was spectro-
photometrically evaluated at 260 nm.
polymerase chain reaction
Sample DNA (100–300 ng) from each extraction were
used for polymerase chain reaction (PCR) on a DNA
thermal cycler (Touch Down, HYBAID). To control the
integrity and the suitability of the isolated DNA and ⁄ or
the presence of PCR-inhibitory substances, each speci-
men was confirmed by successful amplification of a
fragment of the b-globin gene using the primers
previously described, which resulted in an amplified
product of 260 bp.34
Two oligonucleotide primers, homologous to the
highly conserved L1 region of the HPV genome, were
used to assess the presence of the HPV genome.3 The
sequence was as follows: GP5+ (sense), 5¢-TTT
GTTACTGTGGTAGATACTAC-3¢ and GP6+ (anti-
sense), 5¢-GAAAAATAAACTGTAAATCATATTC-3¢.
The amplified product was of 150 bp. All the primers
used were synthesized in an oligonucleotide synthesizer
(PRIMM). To detect the specific HPV subtype, the
HPV+ specimens were sequenced using the GP5+
primer. Amplification reactions were set up in a final
volume of 100 ll containing: 100–300 ng of the
extracted sample, 1 · Taq buffer [20 mm Tris–HCl
(pH 8.4); 50 mm KCl, 2.5 mm MgCl2], 200 lm of each
of the four dNTPs, 100 pm of each of the primers; 2 U
Taq DNA Polymerase (Gibco, BRL, Carlsbad, CA, USA).
After an initial ‘hot start’ of 10 min at 85C, DNA
amplification was performed for 40 cycles, using the
following thermocycle-step parameters: 94C for 1 min
to denature the DNA, 2 min at 55C for annealing, and
Table 1. Summary of primary site, histopathological grading,
and IFI16, pRb, Ki67 expression in 36 head and neck
squamous cell carcinomas
Case Site Grading IFI16 Ki67 pRb
1 TA Low 3* <20% Pos
2 TA High 1 >20% Pos
3 TA High 3 >20% Pos
4 TA High 2 >20% Pos
5 TA Low 2 >20% Pos
6 TA High 1 >20% Neg
7 TA High 2 >20% Pos
8 TA High 2 >20% Pos
9 TA High 2 >20% Neg
10 GL High 0 >20% Neg
11 GL Low 3 <20% Pos
12 GL High 2 >20% Pos
13 GL High 0 >20% Neg
14 GL Low 2 <20% Pos
15 GL Low 3 >20% Pos
16 GL Low 2 <20% Pos
17 GL Low 3 <20% Pos
18 GL Low 2 <20% Pos
19 GL Low 3 <20% Pos
20 GL Low 3 <20% Pos
21 GL High 0 <20% Pos
22 GL High 2 >20% Pos
23 GL Low 2 >20% Pos
24 GL Low 1 >20% Neg
25 SG Low 3 <20% Pos
26 SG Low 3 <20% Pos
27 SG High 0 >20% Neg
28 SG Low 3 <20% Pos
29 SG Low 3 <20% Pos
30 SG Low 1 >20% Pos
31 SG Low 2 <20% Pos
Table 1. (Continued)
Case Site Grading IFI16 Ki67 pRb
32 SG High 1 >20% Neg
33 SG High 1 >20% Pos
34 SG High 2 >20% Neg
35 SG Low 1 <20% Pos
36 SG High 1 >20% Pos
*IFI16 staining: 0, null; 1, weak; 2, nuclear; 3, nuclear
and ⁄ or nucleolar.
TA, Tonsillar area; GL, glottic; SG, supraglottic.
IFI16 expression in HNSCC 563
 2004 Blackwell Publishing Ltd, Histopathology, 45, 560–572.
90 s at 72C with a final extension of 10 min at 72C.
The negative controls were samples with water repla-
cing target DNA in the reaction mixture. Twenty
microlitres of the reaction mixture were analysed by
electrophoresis on 1 or 2% agarose (for b-globin and L1
amplification, respectively) and the reaction products
were visualized by ethidium bromide staining. To avoid
contamination of specimens with viral DNA, standard
precautions concerning spatial separation of pre- and
post-PCR steps, aliquoting of reagents and single use of
scalpels for processing tissue specimens were strictly
followed. A set of negative controls (water, unrelated
genomic DNA) was included during all steps of the
DNA isolation and amplification procedure. None was
positive for HPV DNA.
statistical analysis
The significance of the correlation between the values
was estimated by a v2 test or Fisher’s exact test for
categorical data.
All patients had a 2-year minimum follow-up. The
date of diagnosis was considered the starting day of
observation; patients who died of other causes without
evidence of disease or who were unavailable for follow-
up were either censored at the time of death or at last
follow-up. The overall survival curves were calculated
according to the Kaplan–Meier method. The log rank
test was used to test for differences between subgroups.
All P-values were considered statistically significant
if £ 0.05. All data were processed with GraphPad
Prism statistical software (San Diego, CA, USA).
Results
immunohistochemical studies
The morphological features that best characterized
HNSCCs were related to keratinization and included the
presence of intracellular bridges, extracellular depos-
ition of keratinaceous amorphous material, cytoplas-
mic keratinization, and the formation of keratin pearls.
The tumours were therefore divided into well kerati-
nized (low grade) and poorly keratinized (high grade).
The former were characterized by variably sized nests of
squamous cells with abundant highly keratinized
cytoplasm and numerous central keratin pearls. The
central portions of the nests often contained large
concentric keratin whorls. Individual tumour cells had
distinct borders, abundant homogeneous cytoplasm
with a clear, glassy appearance, and numerous easily
identified cytoplasmic bridges. At the periphery of the
tumour, this histological type tended to have an
infiltrative pattern with small groups, cords or bands
of tumour cells advancing into the adjacent stroma. In
contrast, the poorly keratinized tumours were com-
posed of a relatively monomorphic population of small
ovoid to spindled cells with a high nuclear to cytoplas-
mic ratio arranged in variably sized sheets, nests, and
cords. Individual cells often had indistinct cell borders,
relatively small amounts of cytoplasm with minimal or
no squamous maturation and resembled immature
basal cells; keratin pearls and cytoplasmic bridges were
very rare. Tumour necrosis was mostly seen in the
central portions of the nests. By using these two
categories we divided our series of cases into 19 low-
grade and 17 high-grade carcinomas.
Two patterns of IFI16 intracellular distribution were
observed, as illustrated in Figure 1: (i) strong nucleolar
staining with weak or negative nuclear expression
(Figure 1A); (ii) diffuse or granular nuclear stain-
ing (Figure 1B). By contrast, immunoreactivity for
IFI16 was not detected in other neoplastic lesions
(Figure 1C). Overall, in low-grade carcinomas, tumour
nests displayed a peculiar IFI16 distribution: the
central keratinized cells were mostly negative, as
shown in Figure 2, and tended to be sharply demar-
cated from the more peripheral, often single layer of
positive basal cells resembling Figure 1A. The advan-
cing front of the tumour into the adjacent stroma
tended to be pushing or expansile rather than infiltra-
ting and most of its cells were positive. In high-grade
tumours, IFI16 immunoreactivity mostly resembled
Figure 1B, showing weak nuclear granular staining.
IFI16 immunostaining was assessed semiquantitatively
according to both the proportion of positively stained
cells and the IFI16-staining pattern as follows: grade 0
(no staining); grade 1 (<50% of positive cells with weak
nuclear staining resembling Figure 1B); grade 2 (>50%
of positive cells with strong nuclear staining); grade 3
(>50% of positive cells with a prominent nucleolar
staining resembling Figure 1A). The difference between
grades 2 and 3 relates to the IFI16 nucleolar localiza-
tion and more uniform staining in the nucleoplasm
which resembles its normal expression pattern as
previously reported.25 In Table 1, the specimens are
categorized according to the primary tumour site,
clinical data, and histological features and all the IFI16
immunoreactivity results are reported. Nine of 17 high-
grade tumours were IFI16– or weakly positive, scored
as grade 0 and 1. By contrast, 16 of 19 low-grade
tumours were IFI16+, scored as grade 2 and 3. There
was a statistical relationship between grading and
IFI16 expression; grades 2 and 3 IFI16 expression were
related to low-grade carcinoma (P ¼ 0.032). This
correlation was higher when only nucleolar (grade 3)
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IFI16 expression was considered (P ¼ 0.0034). No
correlation existed between IFI16 expression and
tumour site, patient age or gender.
Serial sections were also analysed for their prolifer-
ative activity by immunostaining for Ki67. In normal
epithelia Ki67+ cells were mostly located in the basal
cell layer, in the tumour mass; they were randomly
Figure 1. Examples of immunostaining patterns for the IFI16
protein. A, Strong nucleolar staining with weak or negative nuclear
expression. B, Diffuse and granular nuclear staining. C, Negative
staining. Immunohistochemical staining shows IFI16-positive and
-negative cells in brown (DAB substrate) and counterstained with
haematoxylin, respectively.
Figure 2. Representative photomicrographs of the immunostaining
patterns of IFI16, Ki67, and pRb in a case of low-grade HPV+
squamous cell carcinoma of the larynx. Immunohistochemical
staining shows positive and negative cells in brown (DAB substrate)
and counterstained with haematoxylin, respectively.
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distributed in all levels of the epithelium and nearly all
cells of the invading front were positive. In low-grade
squamous cell carcinomas, positive Ki67 staining was
detected only in cells at the periphery of the tumour cell
nests (Figure 2). The central keratinizing areas and
adjacent tumour cells were negative. Conversely, the
staining was more diffuse in high-grade carcinomas
(Figure 3). Overall, the proliferative activity, as defined
by Ki67 immunostaining, was significantly related to
tumour differentiation and histological diagnosis; 16 of
17 high-grade tumours displayed >20% Ki67+ cells as
reported in Table 1. Ten of these highly proliferating
lesions showed negative or weak nuclear IFI16 stain-
ing. By contrast, 13 of 19 low proliferating lesions
strongly expressed IFI16 and displayed grades 2 and 3.
Our results indicate that intense nuclear and ⁄ or
nucleolar IFI16 staining strongly correlates with a
lower proliferation rate (P ¼ 0.039).
Since it has been demonstrated that HIN-200
proteins exert their antiproliferative activity through
the pRb pathway,21 we processed sections by immu-
nohistochemistry for the expression of the Rb protein
to correlate IFI16 expression with pRb status. In
normal squamous epithelium, the parabasal cells were
pRb+ and the basal cells showed no detectable pRb.
The normal mucosa adjacent to the carcinoma
stained positive in all cases. The pattern of Rb
staining tended to be diffuse with variable intensity
of nuclear staining. Positive nuclei were randomly
distributed throughout the tumour with a higher
number of positive cells in low-grade as opposed to
high-grade tumours. Tumours with more than 30% of
nuclei staining were interpreted as positive. Staining
for pRb was detected in 28 cases. As expected, in the
eight negative cases the normal squamous epithelium
from the surrounding area showed a normal pRb
expression pattern. The surrounding dysplasia stained
positive for both pRb and IFI16 proteins, indicating
that loss of expression was dependent on the stage of
progression (Figure 3). Six of these eight Rb– tumours
showed IFI16 staining grade 0 or 1, and all of them
displayed a high proliferation rate as determined by
Ki67 staining, and illustrated in Figure 3. By contrast,
the majority of pRb+ tumours also showed marked
expression of IFI16 (grades 2 and 3, see Figure 2). On
dividing IFI16 staining negative (grades 0 and 1)
versus positive (grades 2 and 3), a significant corre-
lation between IFI16 and Rb expression was observed
(P ¼ 0.009). In the multivariate analysis, IFI16 and
Rb expression retained their significant association
with low grade of proliferation (P ¼ 0.014). Although
the correlation was not absolute, IFI16 nucleolar
staining as shown in Figure 1A and Figure 2 was
more likely to occur in lesions with strong Rb
expression.
Distribution of IFI16 and pRb staining in the high
and low proliferating tumours is summarized in
Figure 4.
Figure 3. Representative photomicrographs of the immunostaining
patterns of IFI16, Ki67, and pRb in a case of high-grade HPV–
squamous cell carcinoma of the larynx. Immunohistochemical
staining shows positive and negative cells in brown (DAB substrate)
and counterstained with haematoxylin, respectively.
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occurrence of hpv sequences and
clinicopathological parameters
In two specimens (from patients with only one spec-
imen available), b-globin DNA could not be amplified,
probably due to disintegrated DNA rather than PCR
inhibition, since PCR products were produced after
adding control HPV DNA. Subsequently, all HPV-DNA-
positive carcinomas were sequenced using the GP5+
primer to determine the specific HPV subtype. Table 2
shows the results obtained by PCR analysis together
with the IFI16 expression pattern and the clinicopath-
ological characteristics of the patients. HPV DNA was
found in 14 of 25 (56%) laryngeal SCC and in five of
nine (56%) tonsillar SCC specimens examined. In the
HPV+ specimens, the high-risk HPV types 16 and 18
were predominantly represented. HPV-16 DNA was
detected in 14 cases (41%), and HPV-18 was detected
in five (15%). For simplicity, in Table 2 IFI16 immuno-
histochemical staining is reported as positive (including
patterns 2 and 3 from Table 1) and negative (including
patterns 0 and 1 from Table 1). HPV+ and IFI16+
cases were predominantly low grade, and 17 out of 19
HPV-DNA-positive cases showed high levels of IFI16
expression with a statistically significant correlation
(P ¼ 0.0035). Of interest is that, among laryngeal
tumours, the correlation between the presence of HPV
DNA and sustained IFI16 expression was higher
(P < 0.0001). Figure 5 illustrates the distribution of
IFI16 expression in relation to HPV status.
Clinicopathological parameters analysed included
age, gender, primary site, tumour extension, nodal
status, clinical stage, tumour grade differentiation,
local control, and follow-up. Follow-up information
was available in all cases. Twelve patients died of
disease during the follow-up period, ranging between
9 and 33 months after the date of diagnosis. Of note,
only one of them showed the highest grade of IFI16
expression. Twenty patients were alive at the end of the
follow-up. The overall survival curves by the Kaplan–
Meier method (Figure 6) showed a better prognosis for
patients whose tumours had the highest grade of IFI16
expression (P ¼ 0.034). Since grade 3 reflects its
cellular localization in normal cells where it exerts its
physiological action, one can hypothesize that in these
tumours IFI16 can still regulate epithelial cell growth.
This finding is in line with the highest correlation
observed between grade 3 IFI16 expression and low-
grade carcinomas. By contrast, no association was
observed between HPV+ or HPV– tumours and patient
demographics or disease status. Comparison of HPV+
and HPV– subgroups showed no significant differences
in overall survival (P ¼ 0.239).
Discussion
A hallmark of HNSCC is its extensive clinical hetero-
geneity.35 This makes it difficult to assess its malig-
nancy and predict the outcome of treatment. Molecular
markers defining certain genotypes and phenotypes
and representing tumour subgroups with more homo-
geneous behaviour must thus be found. Tumours
associated with oncogenic HPV may represent such a
subgroup.36,37
Although some of IFI16’s biochemical properties and
molecular interactions have been delineated in vitro, its
physiological role and in vivo expression in pathological
situations such as tumours have not been investi-
gated.38,39 This study is the first systematic investiga-
tion of IFI16 expression in a series of primary HNSCCs
according to their histopathological grading and pro-
liferation index. We have demonstrated a strong
correlation between IFI16 expression and histopatho-
logical grade: sustained IFI16 immunoreactivity was
uniformly observed in low-grade and was barely
detectable or negative in high-grade HNSCC. Interest-
ingly, most HPV+ cases expressed high IFI16 levels.
The retinoblastoma (Rb) gene product is constitu-
tively expressed in the nucleus of every normal cell.40
Alterations in the gene that result in loss of the Rb
protein or in production of an abnormal protein
product have been found in a wide variety of epithelial
tumours, including breast carcinoma, bladder cancer,
and non-small-cell lung cancer.41,42 Previous studies
have demonstrated that pRb immunoreactivity in
HNSCC is enhanced in well-keratinized as opposed to
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Figure 4. Relationship between proliferation index, pRb immuno-
staining and IFI16 expression levels scored as positive (grades 2
and 3) and negative (grade 0 and 1) in 36 head and neck squamous
cell carcinomas.
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Table 2. Clinicopathological parameters, IFI16 and HPV detection in 36 head and neck squamous cell carcinomas
Case Age Sex
Primary







1 47 M TA 3 2b IV Low Pos Neg Yes DID 37–
2 70 M TA 2 2b IV High Neg 16 Yes DODM 22**
3 49 M TA 2 1 III High Pos Neg Yes NED 58††
4 60 F TA 1 2 IV High Pos Neg Yes NED 25
5 48 M TA 2 0 II Low Pos Neg Yes NED 44
6 73 M TA 2 2 IV High Neg 18 Yes DODM 15
7 56 M TA 1 0 I High Pos 16 No DOLD 18‡‡
8 61 M TA 2 1 III High Pos 18 Yes NED 25
9 56 F TA 2 0 II High Pos 16 Yes NED 24
10 63 M GL 2 2 IV High Neg Neg Yes DODM 14
11 45 M GL 1a 0 I Low Pos 16 Yes NED 30
12 59 M GL 3 2b IV High Pos 16 Yes DODM 20
13 69 M GL 2 0 II High Neg Neg Yes NED 21
14 59 M GL 1a 0 II Low Pos 16 Yes NED 78
15 57 M GL 2 0 II Low Pos 16 No DOLD 21
16 73 M GL 1a 0 I Low Pos ND§§ Yes NED 84
17 70 M GL 1 0 I Low Pos 16 Yes NED 82
18 70 M GL 3 2b IV Low Pos 16 Yes DODM 33
19 74 M GL 3 0 III Low Pos 16 Yes NED 42
20 72 M GL 1a 0 I Low Pos 16 Yes DID 40
21 60 F GL 3 2 IV High Neg ND No DOLD 20
22 69 M GL 3 0 III High Pos 18 Yes NED 80
23 87 F GL 1b 0 I Low Pos 16 Yes NED 98
24 64 M GL 4 0 IV Low Neg Neg No DOLD 11
25 59 M SG 4 2c IV Low Pos Neg Yes DID 30
26 59 M SG 1 0 I Low Pos Neg Yes NED 42
27 58 M SG 1 0 I High Neg Neg Yes NED 40
28 61 M SG 1 0 I Low Pos 16 Yes NED 70
29 67 M SG 3 0 III Low Pos 16 Yes NED 36
30 69 M SG 2 2c IV Low Neg Neg Yes NED 48
31 75 M SG 4 1b IV Low Pos 18 No DOLD 9
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been reported that pRb levels in HPV E7- expressing
cells are low due to degradation through the ubiquitin–
proteasome pathway.45–47 Our results, too, indicate
that pRb immunostaining occurs mainly in low-grade
tumours. In addition, we observed that pRb signifi-
cantly associates with IFI16 expression and is not
affected by the presence of the HPV DNA, as shown by
the similar immunoreactivity score of the HPV+ and
HPV– groups (P ¼ 0.417). By contrast, 17 out of
19 HPV-DNA-positive cases showed high-grade IFI16
expression, a statistically significant observation
(P ¼ 0.0035) consistent with Laimins et al.’s demon-
stration that IFN-inducible genes are major targets of























Figure 5. Relationship between HPV status and IFI16 expression
levels scored as positive (grades 2 and 3) and negative (grade 0 and 1)




















Figure 6. Cumulative prognostic value of IFI16 expression in 36












32 55 M SG 2 0 II High Neg Neg Yes DID 13
33 71 F SG 2 0 II High Neg Neg Yes NED 48
34 55 M SG 3 1 IV High Pos 18 No DOLD 10
35 58 M SG 3 0 III Low Neg Neg Yes NED 32
36 61 M SG 2 2 IV High Neg Neg Yes DODM 30
*TA, Tonsillar area; GL, glottic; SG, supraglottic.
†Tumour not more than 20 mm in greatest dimension (T1); tumour more than 20 mm but not more than 40 mm (T2); tumour
more than 40 mm (T3); tumour invades adjacent structures (T4).
‡No regional lymph node metastasis (N0); single ipsilateral lymph node metastasis, 30 mm or less in greatest dimension (N1);
single ipsilateral lymph node metastasis, more than 30 mm but not more than 60 mm in greatest dimension (N2a); metastasis in
multiple ipsilateral lymph nodes, none more than 60 mm in greatest dimension (N2b); metastasis in bilateral or contralateral
lymph nodes, none more than 60 mm in greatest dimension (N2c); metastasis in a lymph node more than 60 mm in greatest
dimension (N3).
§IFI16 staining: Neg, grades 0 and 1; Pos, grades 2 and 3.
–Died of an intercurrent disease.
**Died of distant metastasis with local control.
††No evidence of disease at the indicated months.
‡‡Died of the local disease.
§§Not determined.
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HNSCC can easily be overestimated if assessed by PCR
only, as in this study, and further investigations are
needed to establish a causal association between HPV
infection and IFI16 expression in HNSCC, we may
assume that IFI16 up-regulation in HPV+ tumours is a
predictive marker of a low proliferation rate.
During the cell cycle, the active underphosphoryl-
ated pRb is only present in G0 ⁄ G1 phase and acts as a
negative regulator of its progression.48 The transcrip-
tional activator E2F ⁄ DP family is preferentially bound
to the hypophosphorylated Rb protein and results in
the functional inactivation of E2F, thereby blocking its
growth-promoting activity mainly during G0 ⁄ G1.49
During transition to the S-phase, pRb is inactivated
upon phosphorylation by cyclin-dependent-kinases
(cdks), causing a substantial decrease in E2F ⁄ pRb
binding.50 This allows E2F to function as a transcrip-
tional activator on target promoters and express
certain genes containing E2F binding sites at the
beginning of S-phase proceeding to uncontrolled cell
growth.
In the mouse system overexpression of Ifi204, the
homologue of the IFI16 gene, retarded cell prolifer-
ation, delayed G1 progression into S-phase and accu-
mulated cells with a DNA content equivalent to cells
arrested in G1.
18,19 These effects were strictly depend-
ent on the association of progression with Rb, suggest-
ing that Ifi204 protein controls the cell cycle through
the pRb system.21 Importantly, Xin et al. have reported
that ectopic expression of IFI16 in prostate cancer cell
lines results in colony formation inhibition that differs
with respect to expression of functional pRb; the
maximum inhibition was seen in LNCaP (these cells
express functional Rb) and minimum inhibition was
seen in DU-145 cells (these cells do not express
functional Rb).27 Consistent with these observations,
we have shown that IFI16 and pRb immunostaining
overlaps in those low-growth tumours and conversely
are both barely detectable in more aggressive tumours.
The strong association between simultaneous expres-
sion or alteration of IFI16 and pRb has some inter-
esting implications. The first is that in vivo
immunohistochemical analysis of HNSCC reinforces
the previous results showing a close association of the
mouse Ifi204 protein with the pRb system.21 The
second implication is that sustained IFI16 expression
correlates with a lower proliferation rate and a higher
differentiation grade, and may thus be of assistance in
prognosis. The third is that, since these proteins are
considered as negative regulators of the cascade of
events involved in cell growth, their simultaneous
down-regulation suggests a definite and irreparable
alteration of mechanisms responsible for cell prolifer-
ation. In this context, we analysed the clinical rele-
vance of IFI16 expression and found a significant
correlation between a high score for IFI16 expression
and overall patient survival (P ¼ 0.034).
A high proliferation rate has been correlated with
aggressive behaviour in tumours of various sites. In
HNSCC there are data which indicate that cell prolif-
eration indices are reliable and reproducible indicators
of aggressiveness.51,52 Consistent with these observa-
tions, in this study we report that IFI16 expression
correlates inversely with proliferative activity, evalu-
ated as the percentage of Ki67+ tumour cells. The
lower proliferation rate of strongly IFI16+ tumours
may be related to the antiproliferative activity of the
HIN-200 proteins. Clearly, both human and mouse
HIN-200 proteins can regulate gene transcription and
cell growth. By contrast, it is still unclear whether their
cell cycle regulation is a direct consequence of tran-
scription regulation, i.e. direct binding to transcription
factors such as NF-jB, AP-1, or E2F ⁄ DP-1, or induced
indirectly by their binding to cell regulatory proteins,
such as pRb.15–17 In support of the latter hypothesis,
we found that the majority of squamous cell carcin-
omas demonstrated a significant correlation between
IFI16 and pRb expression, suggesting that, as observed
in the mouse, cell cycle regulation by IFI16 may partly
depend on its interaction with the pRb pathways.
Our data strongly suggest the the IFN-inducible gene
product IFI16 plays a role in the growth regulation of
HNSCC. The finding of high IFI16 levels in low-grade
tumours together with its reported antiproliferative
activity supports this hypothesis. Although the role of
IFI16 in human HNSCC is unknown, the significant
correlation between its levels, pRb immunoreactivity,
low histopathological grading, low proliferation index,
and HPV presence suggests that IFI16 expression may
identify a subset of less aggressive tumours. In this
regard, we found that the highest grade of IFI16
expression appeared to be a good variable in predicting
overall survival in HNSCC. In summary, our data,
together with the recent observations by Xin et al.
demonstrating that IFI16 contributes to cellular sen-
escence and irreversible growth arrest of prostate
epithelial cells, suggest that loss of IFI16 function
may provide a proliferation advantage to cells by
bypassing cell cycle check points.30 Further work is in
progress to determine whether expression of IFI16
function in head and neck squamous epithelial cells
could serve as a molecular marker to follow the severity
of squamous hyperplasia and intraepithelial neoplasia
in patients and, more importantly, to determine whe-
ther the loss of IFI16 function could serve as a reliable
marker for development of HNSCC at an early stage.
570 B Azzimonti et al.
 2004 Blackwell Publishing Ltd, Histopathology, 45, 560–572.
Acknowledgements
Supported by Associazione Italiana per la Ricerca sul
Cancro (AIRC), Lega italiana per la lotta contro i
tumori, section of Novara, Special Project Oncology
‘Compagnia di San Paolo’, and MIUR (‘Program 40%’
to S.L. and M.G.). B.A. was supported by a fellowship
from Fondazione Italiana per la Ricerca sul Cancro
Onlus, and M.D.A. by a short-term fellowship from
EMBO. M.M. is a recipient of a Research Fellowship
from the Fondazione Internazionale di Ricerca in
Medicina Sperimentale, Turin.
References
1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics 1996.
CA Cancer J. Clin. 1996; 65; 5–27.
2. Azzimonti B, Hertel L, Aluffi P et al. Demonstration of multiple
HPV types in laryngeal premalignant lesions using polymerase
chain reaction and immunohistochemistry. J. Med. Virol. 1999;
59; 110–116.
3. Houten VMM, Snijders PJF, Brekel MWM et al. Biological
evidence that human papillomaviruses are etiologically involved
in a subgroup of head and neck squamous cell carcinomas. Int. J.
Cancer 2001; 93; 232–235.
4. Snijders PJF, Scholes AGM, Hart CA et al. Prevalence of mucos-
otropic human papillomaviruses in squamous-cell carcinoma of
the head and neck. Int. J. Cancer 1996; 66; 464–469.
5. Syrjanen K, Syrianen S, Lamberg M, Pyrhonen S, Nuutinen J.
Morphological and immunohistochemical evidence suggesting
human papillomavirus (HPV) involvement in oral squamous cell
carcinogenesis. Int. J. Oral Surg. 1983; 12; 418–424.
6. Gillison ML, Koch WM, Capone RB et al. Evidence for a causal
association between human papillomavirus and a subset of head
and neck cancers. J. Natl Cancer Inst. 2000; 92; 709–720.
7. Zur Hausen H. Papillomavirus causing cancer: evasion from
host-cell control in early events in carcinogenesis. J. Natl Cancer
Inst. 2000; 78; 1–29.
8. Zur Hausen H. Papillomaviruses and cancer: from basic studies
to clinical application. Natl Rev. Cancer 2002; 2; 342–350.
9. Darnell JEJ, Kerr IM, Stark GR. Jak-STAT pathways and
transcriptional activation in response to IFNs and other extra-
cellular signaling proteins. Science 1994; 264; 1415–1421.
10. Barnard P, McMillan NA. The human papillomavirus E7
oncoprotein abrogates signaling mediated by interferon-alpha.
Virology 1999; 259; 305–313.
11. Ronco LV, Karpova AY, Vidal M, Howley PM. Human papillo-
mavirus 16, E6 oncoproteins binds to interferon regulatory
factor-3 and inhibits its transcriptional activity. Genes Dev. 1998;
12; 2061–2072.
12. Chang YE, Laimins LA. Microarray analysis identifies interferon-
inducible genes and Stat-1 as major transcriptional targets of
human papillomavirus Type 31. J. Virol. 2000; 74; 4174–
4182.
13. Chang YE, Laimins LA. Interferon-inducible genes are major
targets of human papillomavirus type 31: insights from micro-
array analysis. Dis. Markers 2001; 17; 139–142.
14. Nees M, Geoghegan JM, Hyman T, Frank S, Miller L, Woodworth
CD. Papillomavirus type 16 oncogenes downregulate expression
of interferon-responsive genes and upregulate proliferation-asso-
ciated and NF-kB-responsive genes in cervical keratinocytes.
J. Virol. 2001; 75; 4283–4296.
15. Landolfo S, Gariglio M, Gribaudo G, Lembo D. The Ifi 200 genes:
an emerging family of IFN-inducible genes. Biochimie 1998; 80;
721–728.
16. Lengyel P, Choubey D, Li SJ, Datta B. The interferon-activatable
gene 200 cluster: from structure toward function. Sem. Virol.
1995; 6; 203–213.
17. Johnstone RW, Trapani JA. Transcription and growth regulatory
functions of the HIN-200 family of proteins. Mol. Cell Biol. 1999;
19; 5833–5838.
18. Lembo D, Angeretti A, Benefazio S et al. Constitutive expression
of the interferon-inducible protein p202 in NIH 3T3 cells affects
cell cycle progression. J. Biol. Regul. Homeost. Agents 1995; 9;
42–46.
19. Lembo M, Sacchi C, Zappador C et al. Inhibition of cell prolifer-
ation by the interferon-inducible 204 gene, a member of the Ifi
200 cluster. Oncogene 1998; 16; 1543–1551.
20. Gribaudo G, Riera L, De Andrea M, Landolfo S. The antiprolif-
erative activity of the murine interferon-inducible Ifi200 proteins
depends on the presence of two 200 amino acid domains. FEBS
Lett. 1999; 456; 31–36.
21. Hertel L, Rolle S, De Andrea M et al. The retinoblastoma protein
is an essential mediator that links the interferon-inducible 204
gene to cell-cycle regulation. Oncogene 2000; 19; 3598–3608.
22. De Andrea M, Ravotto M, Noris E et al. The interferon-inducible
gene, Ifi204, acquires malignant transformation capability upon
mutation at the Rb-binding sites. FEBS Lett. 2002; 515; 51–57.
23. Dawson MJ, Elwood NJ, Johnstone RW, Trapani JA. The IFN-
inducible nucleoprotein IFI16 is expressed in cells of the
monocyte lineage, but is rapidly and markedly down-regulated
in other myeloid precursor populations. J. Leukoc. Biol. 1998; 64;
546–554.
24. Gariglio M, De Andrea M, Lembo M et al. The murine homolog of
the HIN 200 family, Ifi 204, is constitutively expressed in
myeloid cells and selectively induced in the monocyte ⁄ macro-
phage lineage. J. Leukoc. Biol. 1998; 64; 608–614.
25. Gariglio M, Azzimonti B, Pagano M et al. Immunohistochemical
expression analysis of the human interferon-inducible gene
IFI16, a member of the HIN200 family, not restricted to
hematopoietic cells. J. Interferon Cytokine Res. 2002; 22; 815–
821.
26. Wei W, Clarke CJ, Somers GR et al. Expression of IFI16 in
epithelial cells and lymphoid tissues. Histochem. Cell Biol. 2003;
119; 45–54.
27. Xin H, D’Souza S, Fang L, Lengyel P, Choubey D. p202, an
interferon-inducible negative regulator of cell growth, is a target
of the adenovirus E1A protein. Oncogene 2001; 20; 6828–6839.
28. Mori JY, Rashid A, Leggett BA et al. Instabilotyping: compre-
hensive identification of frameshift mutations caused by coding
region microsatellite instability. Cancer Res. 2001; 61; 6046–
6049.
29. Varambally S, Dhanasekaram SM, Zhou M et al. The polycomb
group protein EZH2 is involved in progression of prostate cancer.
Nature 2002; 419; 624–629.
30. Xin H, Curry J, Johnstone RW, Nickoloff BJ, Choubey D. Role of
IFI16, a member of the interferon-inducible p200-protein family,
in prostate epithelial cellular senescence. Oncogene 2003; 22;
4831–4840.
31. Shanmugaratnam K, Sobin LN. Histological typing of tumors of the
upper aerodigestive tract and ear, 2nd edn. Berlin: Springer, 1987.
32. Wiernik G, Millard PR, Haybittle JL. The predictive value
of histological classification into degrees of differentiation of
IFI16 expression in HNSCC 571
 2004 Blackwell Publishing Ltd, Histopathology, 45, 560–572.
squamous cell carcinoma of the larynx and hypopharynx
compared with the survival of patients. Histopathology 1991;
19; 411–417.
33. Wright DK, Manos MM. Sample preparation from paraffin-
embedded tissues. In Innis MA, Gelfand DH, Snisky JJ, White TJ
eds. PCR protocols. A guide to method and applications. New York:
Academic Press, 1990; 153–158.
34. Saiki RK, Scharf S, Faloona F et al. Enzymatic amplification of
b-globin genomic sequences and restriction site analysis for
diagnosis of sickle cell anemia. Science 1985; 230; 1350–1354.
35. Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck
cancer. N. Engl. J. Med. 2001; 345; 1890–1900.
36. Gillison ML, Shah KV. Human papillomavirus-associated head
and neck squamous cell carcinoma: mounting evidence for an
etiologic role for human papillomavirus in a subset of head and
neck cancers. Oncology 2001; 13; 183–188.
37. Mork J, Lie AK, Glattre E et al. Human papillomavirus infection
as a risk factor for squamous-cell carcinoma of the head and
neck. N. Engl. J. Med. 2001; 344; 1125–1131.
38. Johnstone RW, Kerry JA, Trapani JA. The human interferon-
inducible protein IFI16 is a repressor of transcription. J. Biol.
Chem. 1998; 273; 17172–17177.
39. Johnstone RW, Wei W, Greenway A, Trapani JA. Functional
interaction between p53 and the interferon-inducible nucleo-
protein IFI16. Oncogene 2000; 19; 6033–6042.
40. Mulligan G, Jacks T. The retinoblastoma gene family: cousins
with overlapping interests. Trends Genet. 1998; 14; 223–229.
41. Harbour JW, Lai S-L, Whang-Peng J, Gazdar AF, Minna JD, Kaye
FJ. Abnormalities in structure and expression of the human
retinoblastoma gene in SCLC. Science 1988; 241; 353–357.
42. Lee EY-HP, To H, Shew J-Y, Bookstein R, Scully P, Lee W-H.
Inactivation of the retinoblastoma susceptibility gene in human
breast cancer. Science 1988; 241; 218–221.
43. Goussia A, Ellioachim Peschos D, Assimakopoulos D,
Vougiouklakis T, Skevas A, Agnantis N. Immunohistochemical
expression of cathepsin D in laryngeal epithelial lesions: corre-
lation with CD44 expression, p53 and Rb status and proliferation
associated indices. Anticancer Res. 1999; 19; 3055–3060.
44. Ioachim E, Assimakopoulos D, Agnantis NJ, Peschos D, Zissi A,
Skevas A. Altered patterns of retinoblastoma gene product
expresson in benign, premalignant and malignant epithelium
of the larynx: an immunohistochemical study including corre-
lation with p53, bcl-2 and proliferating indices. Anticancer Res.
1999; 19; 541–546.
45. Boyer SN, Wazer DE, Band V. E7 protein of human papilloma-
virus-16 induces degradation of retinoblastoma protein through
the ubiquitin–proteasome pathway. Cancer Res. 1996; 56; 4620–
4624.
46. Giarre` M, Caldeira S, Malanchi I, Ciccolini F, Leao MJ, Tomma-
sino M. Induction of pRb degradation by the human papilloma-
virus type 16, E7 protein is essential to efficiently overcome
p16INK4a-imposed G1 cell cycle arrest. J. Virol. 2001; 75; 4705–
4712.
47. Zehbe I, Ra¨tsch A, Alunni-Fabbroni M et al. Overriding of cyclin-
dependent kinase inhibitors by high and low risk human
papillomavirus types: evidence for an in vivo role in cervical
lesions. Oncogene 1999; 18; 2201–2211.
48. Goodrich DW, Wang NP, Qian Y-W, Lee EY-HP, Lee W-H. The
retinoblastoma gene product regulates progression through the
G1 phase of the cell cycle. Cell 1991; 67; 293–302.
49. Dyson N. The regulation of E2F by pRB-family proteins. Genes
Dev. 1998; 12; 2245–2262.
50. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative
regulators of G1-phase progression. Genes Dev. 1999; 13; 1501–
1512.
51. Munk-Wikland E, Edstrm S, Jungmark E, Aauer G. Nuclear DNA
content, proliferating-cell nuclear antigen (PCNA) and p53
immunostaining in predicting progression of laryngeal cancer
in situ lesions. Int. J. Cancer 1994; 56; 65–96.
52. Valente G, Giusti U, Kerim S et al. High prognostic impact of
growth fraction parameters in advanced stage laryngeal squa-
mous cell carcinoma. Oncol. Rep. 1999; 6; 289–293.
572 B Azzimonti et al.
 2004 Blackwell Publishing Ltd, Histopathology, 45, 560–572.
